Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH

PartnershipPositive

AI Analysis

Summary

Ribo and Madrigal Pharmaceuticals announced the achievement of an important first milestone in the development of new siRNA therapies for MASH in a collaboration between the two companies.

Outcome Details

Achievement of first important milestone in advancement of new siRNA therapies for MASH

Importance:6/10

Sentiment:

0.60

siRNAMASHcollaborationpartnershiptherapeutic development

Related Companies

$06938.HK $MDGL

Read the original article

Published by PR Newswire Pharma on July 2, 2026 6:27 AM

Read Original